Provided by Tiger Trade Technology Pte. Ltd.

T2 Biosystems

0.0115
+0.00054.55%
Volume:2.68K
Turnover:29.65
Market Cap:322.52K
PE:0.00
High:0.0115
Open:0.0110
Low:0.0110
Close:0.0110
52wk High:0.5300
52wk Low:0.0002
Shares:28.05M
Float Shares:14.95M
Volume Ratio:0.27
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0799
EPS(LYR):-19.1867
ROE:-622.14%
ROA:-84.85%
PB:-0.03
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
T2 Biosystems
Exchange:
PINK
Establishment Date:
2006
Employees:
113
Office Location:
101 Hartwell Avenue,Lexington,Massachusetts,United States
Zip Code:
02421
Fax:
- -
Introduction:
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.